fibrosis

Kidney

Biotech

CSL pays $355M to co-develop Alentis’ ph. 2-stage fibrosis drug

Australia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.

James Waldron Oct 5, 2026 4:14am

MA combine

Skye and Redx combine with $125M to advance fibrosis assets

Aug 14, 2026 2:05pm

ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin

Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am

liver

Roche launches liver fibrosis blood test for MASLD

May 7, 2025 10:30am

money road map

Alentis raises $181M series D to bring ADCs to the clinic

Nov 12, 2024 7:00am

Lung Fibrosis

Surrozen's Wnt mimetic antibody works in mice with lung fibrosis

Apr 4, 2024 4:30am